Targeting Integrin Pathways: Mechanisms and Advances in Therapy

The document discusses the role of integrins, vital cell-adhesion transmembrane receptors, in various diseases and their potential as therapeutic targets. Integrins have been pharmacological targets for nearly 40 years, with seven FDA-approved drugs and about 90 integrin-targeting therapies in clinical trials. They play a role in angiogenesis, inflammation, wound healing, cell migration, invasion, proliferation, and aging. They are also involved in diseases like cancer, fibrotic diseases, liver fibrosis, pulmonary hypertension, autosomal dominant polycystic kidney disease, cardiovascular diseases, and autoimmune diseases like inflammatory bowel disease. The document highlights advancements in disease therapies targeting integrin pathways, including small molecules, synthetic mimic peptides, antibodies, ADCs, PDCs, nanotherapeutic agents, CAR T-cell therapy, and imaging agents. However, the need for robust biomarkers, advanced imaging technology, and consideration of adverse effects is emphasized. The document concludes that more research is needed to understand the specific mechanisms and potential therapeutic applications of targeting integrins.